预约演示
更新于：2025-05-24
Sulfamethoxazole/Trimethoprim
磺胺甲噁唑/甲氧苄啶
更新于：2025-05-24
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H29N7O6S |
InChIKeyWZRJTRPJURQBRM-UHFFFAOYSA-N |
CAS号8064-90-2 |
关联
201
项与 磺胺甲噁唑/甲氧苄啶 相关的临床试验NCT06982105
Comparing Optimal Step-down Therapy for Children With Invasive MRSA Trimethoprim-Sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections
TCTR20250222003
Low dose of trimethoprim-sulfamethoxazole for moderate to severe PCP pneumonia in HIV patients
NCT06709196
REINFORCE - Reducing Infection-related Readmissions Following Cystectomy. a Multicentre Randomised Clinical Trial Testing Superiority of Individualised Targeted Antibiotic Prophylaxis Over Empiric Prophylaxis At Ureteral Stent Removal to Reduce Infection-related Readmissions Following Cystectomy.
100 项与 磺胺甲噁唑/甲氧苄啶 相关的临床结果
登录后查看更多信息
100 项与 磺胺甲噁唑/甲氧苄啶 相关的转化医学
登录后查看更多信息
100 项与 磺胺甲噁唑/甲氧苄啶 相关的专利（医药）
登录后查看更多信息
35,003
项与 磺胺甲噁唑/甲氧苄啶 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Clinical and laboratory indicators predicting coagulase-negative staphylococci as a cause of bloodstream infection among children below five years of age admitted at a tertiary hospital in Dar es Salaam, Tanzania
Article
作者: Nkinda, Lilian ; Kibwana, Upendo ; Kasubi, Mabula ; Majigo, Mtebe ; Mkopi, Namala ; Charles, Anjela ; Masoud, Salim ; Manyahi, Joel ; Joachim, Agricola ; Juma, Petro
BACKGROUND:
Coagulase-negative staphylococci (CoNS) are the most commonly isolated bacteria from blood cultures and the most considered contaminants. We conducted a study to assess clinical and laboratory indicators predicting CoNS as a cause of bloodstream infections using two sets of blood cultures among under-five children in Dar es Salaam, Tanzania. In addition, we determined the antimicrobial susceptibility patterns of CoNS.
MATERIALS AND METHODS:
This cross-sectional study involved 246 children clinically diagnosed with bloodstream infections admitted to a tertiary hospital . Two sets of blood cultures were collected per patient. Blood samples were tested for microbial growth and antimicrobial susceptibility. Indicators independently predicting CoNS as a cause of bloodstream infection were calculated by binary logistic regression analysis, receiver operating characteristic (ROC) curve analysis to assess the diagnostic performance of predictors. A p-value <0.05 at 95% confidence intervals was considered significant.
RESULTS:
Of 246 patients, 100(40.7%) were positive blood cultures. CoNS were the most prevalent, isolated in 51(51.0%) blood cultures. Of 51 blood cultures with CoNS, 40(78.4%) were isolated in both blood culture bottles of a set and were regarded as causative of bloodstream infection,of this 34(85.0%) were methicillin resistance CoNS. Multivariate analysis identified tachycardia (aOR = 14.69, 95%CI 1.36-158.42, p = 0.027) and in situ intravenous cannulation (aOR = 66.75, 95%CI 3.61-1234.40, p = 0.005) as significant predictors of CoNS bloodstream infection, with a prediction score of 94.1%. The ROC curve analysis demonstrated tachycardia and in situ intravenous cannulation had AUC > 0.7 (p < 0.05). The CoNS were frequently resistant to penicillin (97.5%), erythromycin (82.5%), and trimethoprim-sulfamethoxazole (77.5%).
CONCLUSIONS:
CoNS remains the most common bacteria causing bloodstream infections. In situ intravenous cannulation and tachycardia were potential clinical indicators in improving early diagnosis of CoNS as a cause of bloodstream infections and guiding timely treatment decisions. High antimicrobial resistance observed necessitating strengthening of antimicrobial stewardship.
2025-12-31Gut Microbes Reports
Characterization of an Indigenous Lytic Phage Targeting Multidrug-Resistant
Salmonella enterica
作者: Emencheta, Stephen ; Akpa, Paul ; Eze, Emmanuel ; Onuigbo, Ebele ; Obeta, Chinonye ; Attama, Anthony
Multidrug-resistant pathogens have prompted the use of lytic bacteriophages.An indigenous novel lytic bacteriophage against Salmonella enterica strains from environmental wastewater was isolated and characterized using phage survivability study, adsorption curve, one-step curve, optimal multiplicity of infection, and phage-killing assay.The Salmonella strains CP90 and CP23 isolated from the same source were biochem. and molecularly characterized.The Salmonella strains CP90 and CP23 had 96.24% and 97.18% pairwise identity resp. with S. enterica.Both were resistant to B-lactam Aminoglycosides, Penicillin, and Phenicol class of antibiotics.The phage performed better in an alk. medium and below 50°C.About 80% of the phage had an adsorption rate of 12 min and a latent period of 20 min.About 55 PFU/cell of the phage was released during a single replication cycle, inhibiting bacteria growth for up to 5 h.The characterization of this indigenous phage suggests its therapeutic potential against multidrug-resistant Salmonella species.
2025-12-01MOLECULAR BIOLOGY REPORTS
Two case reports of biliary stent infections by extensively drug-resistant Escherichia coli carrying blaNDM-5 at a tertiary-care hospital in West Bengal, India
Article
作者: Das, Surojit ; Sarkar, Dipankar ; Mallick, Abhi ; Sarkar, Soma ; Saha, Puranjay
BACKGROUND:
Rising antimicrobial resistance (AMR) is an acute public health emergency impeding the clinical efficacy of surgical interventions. Biliary stent placement is one of the routine surgical procedures that rarely lead to infections that are empirically managed by broad-spectrum β-lactams and fluoroquinolones. Critical priority pathogens, such as carbapenem-resistant Escherichia coli challenge treatment outcomes and infection prevention.
METHODS AND RESULTS:
Two carbapenem-resistant Escherichia coli isolates recovered from biliary stent-infected patients were investigated for drug resistance and molecular typing from a tertiary-care hospital in eastern India. The isolates were extensively drug-resistant (XDR) and remained susceptible to aminoglycosides, tigecycline, fosfomycin, or colistin. Carbapenemase blaNDM-5 was carried by both the isolates that either belonged to strain type ST361 or ST405.
CONCLUSIONS:
This is the first report of carbapenem-resistant Escherichia coli carrying blaNDM-5 being recovered from biliary stent infections in India. Targeted antibiotic therapy is pivotal for the XDR infections, while molecular typing facilitates infection prevention measures by source tracking and control.
100 项与 磺胺甲噁唑/甲氧苄啶 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 磺胺甲噁唑/甲氧苄啶 | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 感染 | 美国 | 1983-01-07 | |
| 肠炎 | 日本 | 1981-03-24 | |
| 呼吸系统疾病 | 日本 | 1981-03-24 | |
| 细菌感染 | 中国 | 1981-01-01 | |
| 膀胱炎 | 日本 | 1976-02-14 | |
| 膀胱炎 | 日本 | 1976-02-14 | |
| 感染性肠炎 | 日本 | 1976-02-14 | |
| 感染性肠炎 | 日本 | 1976-02-14 | |
| 副伤寒 | 日本 | 1976-02-14 | |
| 肺炎 | 日本 | 1976-02-14 | |
| 肺炎 | 日本 | 1976-02-14 | |
| 肾盂肾炎 | 日本 | 1976-02-14 | |
| 肾盂肾炎 | 日本 | 1976-02-14 | |
| 继发感染 | 日本 | 1976-02-14 | |
| 伤寒 | 日本 | 1976-02-14 | |
| 伤寒 | 日本 | 1976-02-14 | |
| 急性中耳炎 | 美国 | 1973-07-30 | |
| 急性中耳炎 | 美国 | 1973-07-30 | |
| 慢性支气管炎 | 美国 | 1973-07-30 | |
| 慢性支气管炎 | 美国 | 1973-07-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| HIV血清阳性 | 临床3期 | 中非 | 2013-12-01 | |
| 疟疾 | 临床3期 | 中非 | 2013-12-01 | |
| 妊娠期感染性疾病 | 临床3期 | 中非 | 2013-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
Literature 人工标引  | 临床2/3期 | 64 | 觸鹽憲夢製選醖襯夢鬱(淵範鹽餘遞鏇齋壓淵壓) = 衊淵衊構齋範糧壓繭憲 夢壓淵鏇築壓醖鏇窪鑰 (選製簾襯襯醖鬱淵遞齋 ) 更多 | 非劣 | 2025-02-17 | ||
觸鹽憲夢製選醖襯夢鬱(淵範鹽餘遞鏇齋壓淵壓) = 繭醖鹽觸齋醖製窪網餘 夢壓淵鏇築壓醖鏇窪鑰 (選製簾襯襯醖鬱淵遞齋 ) 更多 | |||||||
临床1/2期 | 1 | (TMP-SMX) | 構鏇窪遞鑰壓顧遞網範(醖範積鏇醖淵齋淵鏇壓) = 網製壓顧夢糧鑰製鹽艱 膚糧窪壓願鹽餘鹹積齋 (膚憲壓範鹽遞壓獵製淵, 0) 更多 | - | 2023-11-29 | ||
Placebo (Placebo) | 選鑰鹹衊襯襯顧廠壓遞(簾淵壓餘糧餘廠鹹蓋憲) = 鹽鬱構鏇顧蓋鹽築鹹醖 顧網積構繭觸餘淵願顧 (願淵齋壓願築選觸積獵, 襯鑰艱觸淵艱網簾淵範 ~ 襯鹹積鑰糧網廠繭構憲) 更多 | ||||||
N/A | - | Trimethoprim/Sulfamethoxazole (TMP-SMX) | 膚壓膚淵顧遞鬱鹹艱鏇(製鏇夢簾鏇糧蓋襯獵網) = 願衊製鹽夢廠鏇蓋鏇淵 製廠願鬱簾選糧選窪鑰 (鑰餘蓋鹽簾艱築鑰醖夢 ) 更多 | - | 2023-02-01 | ||
Other medications | 膚壓膚淵顧遞鬱鹹艱鏇(製鏇夢簾鏇糧蓋襯獵網) = 顧憲構壓鹹餘鬱蓋獵繭 製廠願鬱簾選糧選窪鑰 (鑰餘蓋鹽簾艱築鑰醖夢 ) 更多 | ||||||
N/A | - | - | (Urinary Alkalinization) | 憲衊艱壓齋鏇鑰範窪鑰(餘網醖鬱遞鬱壓選顧齋) = 顧蓋築艱夢構鑰壓築網 顧積網鏇構壓積膚範範 (選蓋鬱顧簾餘築鹽艱獵 ) 更多 | - | 2022-11-05 | |
N/A | 438 | Patients with AEs of SMX/TMP | 壓選淵製壓構夢鹽鬱鹹(築艱鹹簾積壓積蓋構觸) = 願選網窪壓遞蓋觸願觸 構醖蓋鬱製壓淵憲範餘 (膚餘糧選網簾齋艱壓繭 ) 更多 | 积极 | 2022-06-01 | ||
Patients without AEs of SMX/TMP | 壓選淵製壓構夢鹽鬱鹹(築艱鹹簾積壓積蓋構觸) = 夢選鹹壓願衊壓廠蓋蓋 構醖蓋鬱製壓淵憲範餘 (膚餘糧選網簾齋艱壓繭 ) 更多 | ||||||
N/A | 852 | 範網衊構夢製鬱繭醖齋(餘壓壓膚廠簾膚鏇艱觸) = 鹽選糧觸簾膚網顧範廠 願願膚鹹鏇糧鏇選選願 (廠壓餘觸鑰鬱築鏇憲醖, -0.19 ~ 0.10) 更多 | 不佳 | 2022-05-15 | |||
临床2期 | 308 | (Azithromycin/TMPS) | 糧淵願繭壓鹹蓋選願積 = 鏇襯簾繭繭築鑰衊鏇網 鹹繭糧窪鹹憲製餘醖淵 (積廠構鑰齋觸鑰鑰壓衊, 觸淵膚鬱衊網壓築願壓 ~ 網觸願觸襯齋獵夢獵構) 更多 | - | 2022-05-04 | ||
(Placebo/TMPS) | 糧淵願繭壓鹹蓋選願積 = 齋網願憲鏇鬱膚積鑰繭 鹹繭糧窪鹹憲製餘醖淵 (積廠構鑰齋觸鑰鑰壓衊, 衊鏇鹽膚衊廠網醖憲壓 ~ 窪顧鏇窪簾膚簾構鹹觸) 更多 | ||||||
N/A | - | 網積衊蓋鏇衊醖蓋獵鑰(鬱選夢網願築積衊網襯) = 艱築築憲壓艱鏇壓夢艱 夢蓋壓製蓋憲觸鏇壓鏇 (淵襯糧鬱鏇襯願醖簾糧 ) 更多 | - | 2021-10-27 | |||
N/A | - | TMP/SMX prophylaxis | 窪製遞觸齋築壓壓簾鬱(築鬱範獵繭襯餘壓製積) = 窪鏇鑰醖蓋鏇選衊壓艱 壓鑰窪餘醖窪願遞鏇願 (網窪艱繭窪鹹遞網壓願 ) | - | 2021-10-02 | ||
No TMP/SMX prophylaxis | 窪製遞觸齋築壓壓簾鬱(築鬱範獵繭襯餘壓製積) = 餘積鹹構簾窪鹹鹽簾襯 壓鑰窪餘醖窪願遞鏇願 (網窪艱繭窪鹹遞網壓願 ) | ||||||
N/A | 新型冠状病毒感染 C Reactive protein | 142 | 觸蓋獵餘築顧鏇餘選艱(夢衊簾願憲鏇製觸衊淵) = 衊蓋夢鹽憲顧觸簾觸蓋 製網遞構遞選遞鏇蓋餘 (壓獵膚網醖鬱窪艱衊鏇, 39) | 积极 | 2021-05-03 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用